SEC Form EFFECT filed by Cara Therapeutics Inc.

$CARA
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $CARA alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $CARA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CARA

DatePrice TargetRatingAnalyst
6/13/2024$6.00 → $1.00Buy → Hold
Stifel
6/13/2024$10.00 → $1.00Buy → Hold
Canaccord Genuity
6/13/2024Buy → Hold
Needham
6/13/2024Buy → Neutral
H.C. Wainwright
3/8/2023$13.00 → $6.00Neutral → Underperform
BofA Securities
3/8/2022$17.00 → $20.00Neutral → Overweight
JP Morgan
11/1/2021$33.00Buy
Canaccord Genuity
8/24/2021$33.00 → $35.00Buy
HC Wainwright & Co.
More analyst ratings

$CARA
Press Releases

Fastest customizable press release news feed in the world

See more
  • Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split

    STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) (the "Company"), today announced that a 1-for-12 reverse stock split of its outstanding shares of common stock and reduction in the total number of authorized shares of its common stock from 200,000,000 to 16,666,667 will be effective as of 5:00 p.m. Eastern Time on Monday, December 30, 2024. The Company's common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on Tuesday, December 31, 2024. Following the reverse stock split, the Company's common stock will continue to trade on the Nasdaq Capital Market under the symbol "CARA" with the new CUSIP number, 1

    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement

    Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi has recently completed an approximately $28 million private financing, which, together with Tvardi's existing cash and Cara's anticipated cash balance, is expected to fund the combined company into the second half of 2026 Tvardi anticipates reporting topline data in the second half of 2025 from two Phase 2 clinical programs utilizing its STAT3 inhibitor, TTI-101, including its lead program in idiopathic pulmonary fibrosis and its program in hepatocellular carcinoma Companies to hos

    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Cara Therapeutics Announces Exploration of Strategic Alternatives

    STAMFORD, Conn., July 11, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) today announced that it has engaged Piper Sandler & Co. to act as its financial advisor for the process of exploring and reviewing strategic alternatives. "We are committed to evaluating a range of strategic options to maximize value for our shareholders," said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. "As part of this effort, our Board of Directors has approved a streamlined operating plan focused on cost-containment and cash conservation." There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or

    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CARA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CARA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CARA
SEC Filings

See more

$CARA
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • FDA Approval for KORSUVA issued to CARA THERAPEUTICS INC

    Submission status for CARA THERAPEUTICS INC's drug KORSUVA (ORIG-1) with active ingredient DIFELIKEFALIN has changed to 'Approval' on 08/23/2021. Application Category: NDA, Application Number: 214916, Application Classification: Type 1 - New Molecular Entity

    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CARA
Leadership Updates

Live Leadership Updates

See more
  • Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors

    STAMFORD, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Helen M. Boudreau to its Board of Directors. Ms. Boudreau has more than 30 years of operating experience in a variety of industries, including the biotechnology and pharmaceutical sectors, in addition to serving as a director on numerous public boards. "We are pleased to welcome Helen to the Cara board," said Christopher Posner, President, Chief Executive Officer and Director of Cara Therapeutics. "We look forward to leveraging her

    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • KemPharm Announces Appointment of Christopher Posner as New Independent Director

    24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm's Board of Directors CELEBRATION, Fla., Nov. 29, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS) and neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced the appointment of Christopher Posner to serve on the Company's Board of Directors. Mr. Posner is currently the president and CEO of Cara Therapeutics (NASDAQ:CARA), a commercial-stage biopharmaceutical company.

    $CARA
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors

    STAMFORD, Conn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Lisa von Moltke, M.D., to its Board of Directors. Dr. von Moltke currently serves as Executive Vice President and Chief Medical Officer at Seres Therapeutics, Inc. "We are very pleased to welcome Lisa to our board of directors," said Christopher Posner, President, Chief Executive Officer and Director of Cara Therapeutics. "Her extensive clinical development and pharmacology expertise will be of great value as we continue executing o

    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CARA
Financials

Live finance-specific insights

See more
  • Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement

    Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi has recently completed an approximately $28 million private financing, which, together with Tvardi's existing cash and Cara's anticipated cash balance, is expected to fund the combined company into the second half of 2026 Tvardi anticipates reporting topline data in the second half of 2025 from two Phase 2 clinical programs utilizing its STAT3 inhibitor, TTI-101, including its lead program in idiopathic pulmonary fibrosis and its program in hepatocellular carcinoma Companies to hos

    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

    –Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)– –Completed enrollment of KOURAGE 1 Part A portion of NP pivotal program ahead of schedule; topline efficacy and safety results now expected in 3Q24– –Extended cash runway into 2026 with clinical prioritization strategy and reduction in force– –Conference call today at 4:30 p.m. EST– STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operatio

    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024

    STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate update. To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN. A live audio webcast and archived replay of the call will be available under "Events & Presentations" in the Investors section of the Company's website at www.CaraTherapeutics.com. About Cara Therapeutics Cara Therapeutics is a commercial-stage biopharmaceutical co

    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CARA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more